PAM
BTAI icon

Prudence Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Prudence Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,875
Closed -$272K – 7
2018
Q2 		$272K Hold
1,875
– – 2.61% 6
2018
Q1 		$307K Buy
+1,875
New +$313K 1.52% 7

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prudence Asset Management's BTAI Position: Q3 2018 in Review

Prudence Asset Management sold out of BioXcel Therapeutics (BTAI) in Q3 2018, closing a stake of 1,875 shares — an estimated $272K sold.

Prudence Asset Management first reported a position in BTAI in Q1 2018 and held it in 2 quarters. The position peaked at $307K in Q1 2018. 19 funds tracked by Wall St. Rank hold BTAI as of Q3 2018.

  • Prudence Asset Management reported no remaining BioXcel Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Prudence Asset Management sold 1,875 BioXcel Therapeutics shares in Q3 2018, an estimated $272K.
  • Prudence Asset Management first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 2 quarters.
  • Prudence Asset Management's BioXcel Therapeutics position peaked at $307K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2018.

Based on Prudence Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.